Galmed Pharmaceuticals (GLMD) Competitors $1.38 -0.03 (-2.13%) As of 11:15 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLMD vs. ERNA, ADXN, AEON, RNAZ, EVAX, EPIX, KPRX, VYNE, GOVX, and ALBTShould you be buying Galmed Pharmaceuticals stock or one of its competitors? The main competitors of Galmed Pharmaceuticals include Ernexa Therapeutics (ERNA), Addex Therapeutics (ADXN), AEON Biopharma (AEON), TransCode Therapeutics (RNAZ), Evaxion A/S (EVAX), ESSA Pharma (EPIX), Kiora Pharmaceuticals (KPRX), VYNE Therapeutics (VYNE), GeoVax Labs (GOVX), and Avalon GloboCare (ALBT). These companies are all part of the "pharmaceutical products" industry. Galmed Pharmaceuticals vs. Its Competitors Ernexa Therapeutics Addex Therapeutics AEON Biopharma TransCode Therapeutics Evaxion A/S ESSA Pharma Kiora Pharmaceuticals VYNE Therapeutics GeoVax Labs Avalon GloboCare Ernexa Therapeutics (NASDAQ:ERNA) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk. Which has more risk and volatility, ERNA or GLMD? Ernexa Therapeutics has a beta of 5.62, indicating that its share price is 462% more volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500. Do institutionals and insiders have more ownership in ERNA or GLMD? 70.6% of Ernexa Therapeutics shares are held by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. 1.5% of Ernexa Therapeutics shares are held by company insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media refer more to ERNA or GLMD? In the previous week, Ernexa Therapeutics and Ernexa Therapeutics both had 1 articles in the media. Galmed Pharmaceuticals' average media sentiment score of 0.72 beat Ernexa Therapeutics' score of 0.22 indicating that Galmed Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Ernexa Therapeutics Neutral Galmed Pharmaceuticals Positive Is ERNA or GLMD more profitable? Ernexa Therapeutics' return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Ernexa TherapeuticsN/A N/A -682.08% Galmed Pharmaceuticals N/A -20.69%-18.41% Which has better valuation and earnings, ERNA or GLMD? Galmed Pharmaceuticals has lower revenue, but higher earnings than Ernexa Therapeutics. Ernexa Therapeutics is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioErnexa Therapeutics$580K16.07-$44.54M-$8.31-0.15Galmed PharmaceuticalsN/AN/A-$7.52M-$16.66-0.08 Do analysts rate ERNA or GLMD? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ernexa Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Galmed Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 SummaryGalmed Pharmaceuticals beats Ernexa Therapeutics on 7 of the 11 factors compared between the two stocks. Get Galmed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLMD vs. The Competition Export to ExcelMetricGalmed PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.28M$2.62B$6.08B$10.48BDividend YieldN/A57.78%5.73%4.78%P/E Ratio-0.0822.8384.6926.97Price / SalesN/A759.28596.04130.44Price / CashN/A175.9337.8662.13Price / Book0.145.3012.286.56Net Income-$7.52M$33.06M$3.32B$276.78M7 Day Performance-2.82%-0.97%1.30%0.80%1 Month Performance-7.07%9.32%8.49%4.02%1 Year Performance-60.12%-4.26%72.74%34.82% Galmed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLMDGalmed Pharmaceuticals2.0157 of 5 stars$1.38-2.1%N/A-61.3%$2.28MN/A-0.0820Short Interest ↓ERNAErnexa Therapeutics0.4396 of 5 stars$1.34-1.8%N/A-92.5%$10.24M$580K-0.1610Short Interest ↑ADXNAddex Therapeutics1.075 of 5 stars$9.01-2.1%N/A-15.5%$10.12M$55.35K-28.0930News CoverageAnalyst ForecastShort Interest ↓Gap UpAEONAEON Biopharma0.4888 of 5 stars$0.86+0.7%N/A-98.2%$9.93MN/A4.745Gap DownRNAZTransCode Therapeutics2.2186 of 5 stars$11.96+13.3%$280.00+2,240.4%-99.9%$9.86MN/A0.009Gap DownHigh Trading VolumeEVAXEvaxion A/S1.4453 of 5 stars$7.03+1.1%$11.00+56.6%-30.9%$9.85M$3.34M-5.3360Analyst ForecastShort Interest ↑Trading HaltedEPIXESSA Pharma3.6085 of 5 stars$0.21+0.9%$2.00+870.9%N/A$9.75MN/A-0.3750Dividend AnnouncementKPRXKiora Pharmaceuticals3.157 of 5 stars$2.78+1.1%$10.00+259.7%-20.9%$9.54M$16.02M-0.9610Positive NewsShort Interest ↓VYNEVYNE Therapeutics2.5945 of 5 stars$0.37+3.8%$6.25+1,571.1%-83.4%$9.53M$476K-0.4230Gap UpGOVXGeoVax Labs2.2867 of 5 stars$0.570.0%$8.50+1,379.0%-73.2%$9.15M$6.14M-0.2910Analyst RevisionGap DownALBTAvalon GloboCare1.5627 of 5 stars$2.38+1.9%N/A-30.6%$9.14M$1.33M-0.125Gap Up Related Companies and Tools Related Companies ERNA Competitors ADXN Competitors AEON Competitors RNAZ Competitors EVAX Competitors EPIX Competitors KPRX Competitors VYNE Competitors GOVX Competitors ALBT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLMD) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galmed Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galmed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
